Swiss biotech Nouscom has raised €120 million in an oversubscribed Series D financing to advance NOUS-209, an experimental cancer vaccine designed to prevent tumors in people with Lynch syndrome, into a global registration-enabling clinical trial. Alongside the financing, the company has released new long-term clinical data showing encouraging signs of cancer prevention.
U.K. microbiome company Microbiotica has raised £36 million (€43 million), the first close of a Series C round led by the British Business Bank, to take its ulcerative colitis drug MB310 into Phase 2.
Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule pipeline in endocrinology and immunology, including a potential treatment for congenital adrenal hyperplasia that will compete with drugs developed by Vertex and Neurocrine Biosciences.
Dutch biotech RougeTx has launched with a $58 million (€52 million) series A to take its lead drug RTX-001 toward first-in-human testing in hereditary hemorrhagic telangiectasia (HHT). The round was co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with the European Investment Bank (EIB) participating through Angelini’s Aurea co-investment vehicle.
Swedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether early improvements in pumping function hold up in a larger patient population.
London-based Basecamp Research has raised $140 million (€122 million) in an oversubscribed Series C to expand its biological AI models and move a preclinical therapeutics pipeline toward the clinic. Its first focus is in vivo cell therapy.
German biotech ViferaXS has closed a Series A financing of up to €12 million, including grant funding, to advance its peptide-based cancer immunotherapy into a randomized Phase 2 trial in chronic lymphocytic leukemia (CLL).
Dutch biotech Matisse Pharmaceuticals has raised €14 million in a Series A financing to advance isupartob sodium through Phase 2 development in sepsis.
The French hearing-loss biotech has taken the first formal step toward a potential U.S. listing, as it advances its remaining gene therapy program into the clinic.
Hanover-based Allogenetics has raised €3.8 million in a Pre-Series A round to advance ALG-115, an ex vivo gene therapy for donor lungs, through IND-enabling studies and toward a first-in-human trial planned for late 2027 or early 2028.